PMC8138239_01
BCR-ABL percentage in the course of the disease.
cro-0014-0690-g01.jpg
PMC8138239_01_cro-0014-0690-g01.jpg
F1
BCR-ABL was repeated 3 months later and showed that he was on major molecular response, BCR-ABL1-positive with a BCR-ABL1 to ABL1 percentage ratio of 0.03% (IS), consistent with previous data about the safety and efficacy of 50 mg (Fig. 1).